Mundipharma, SkyePharma sales and marketing update

SkyePharma said the Napp Pharmaceuticals Ltd. affiliate of Mundipharma launched flutiform fluticasone/formoterol in the U.K. to treat asthma. The launch triggers a £4 million ($6.5 million) payment to SkyePharma. The National Health Service (NHS) prices for the drug will be £18 ($29.23) for the 50/5 µg combination; £29.26 ($47.52) for the 125/5 µg combination; and £45.56 ($73.98) for the 250/10 µg combination.

In July, the European Commission approved an MAA for flutiform under the decentralized procedure. According to SkyePharma, the 21 member states are required to grant marketing approval. The product is already approved in Germany, the U.K., Austria, Cyprus, the Netherlands, Norway, Sweden and the Slovak Republic (see BioCentury, Aug. 27). ...